Retatrutide Research Highlights & Key Studies
Summaries of key studies and research findings involving Retatrutide.
Retatrutide has been studied in the TRIUMPH Phase III trials for obesity and type 2 diabetes, showing dose-dependent weight loss of 16.5% to 22.4% over 72 weeks in human studies . Preclinical research has demonstrated effects on brown adipose tissue activation, hepatic ketogenesis, and lipid oxidation. The peptide's triple agonist mechanism establishes a new benchmark for researchers studying multi-receptor metabolic regulation and biased agonism in engineered cell lines.
More about Retatrutide
Research Use Only: This product is intended for laboratory research purposes only. Not for human consumption or clinical use. Always follow applicable laws and regulations.